Skip to main content
. 2012 Feb;19(2):157–166. doi: 10.1128/CVI.05523-11

Table 3.

Association between levels of antibodies (2-fold increment) at 5 and 12 months and incidence of malaria at two time periodsa

Antigen Antibody 5-12 mo
 12-24 mo
Crude
 Adjusted
 Crude
 Adjusted
IRR 95% CI P value IRR 95% CI P value IRR 95% CI P value IRR 95% CI P value
Whole P IgG 1.23 0.96–1.58 0.100 0.99 0.79–1.24 0.923 1.25 0.05–1.50 0.016 1.05 0.90–1.24 0.528
MSP-119 IgG 1.35 1.10–1.67 0.005 1.19 0.95–1.50 0.129 1.46 1.21–1.75 <0.001 1.07 0.88–1.29 0.486
IgG1 1.91 1.39–2.64 <0.001 1.74 1.20–2.52 0.003 1.69 1.20–2.38 0.002 0.85 0.54–1.32 0.464
IgG2 3.65 1.35–9.84 0.013 3.41 1.36–8.53 0.015 2.37 0.83–6.71 0.096 0.73 0.30–1.82 0.504
IgG3 1.62 1.12–2.35 0.010 1.17 0.73–1.88 0.514 1.39 0.88–2.18 0.135 0.74 0.48–1.16 0.191
IgG4 2.91 0.36–23.8 0.299 0.85 0.13–5.42 0.863 4.58 0.89–23.4 0.045 1.13 0.39–3.31 0.824
IgM 1.17 0.99–1.38 0.058 1.07 0.90–1.27 0.426 1.08 0.92–1.27 0.362 1.02 0.89–1.17 0.770
AMA-1 IgG 1.20 0.94–1.53 0.148 1.03 0.81–1.31 0.795 1.23 1.01–1.51 0.042 0.93 0.76–1.13 0.446
IgG1 1.31 0.91–1.88 0.140 1.22 0.80–1.86 0.358 1.84 1.29–2.63 0.001 1.10 0.67–1.56 0.598
IgG2 1.33 0.27–6.42 0.724 0.86 0.17–4.24 0.853 1.62 0.43–6.09 0.469 0.92 0.31–2.70 0.878
IgG3 1.24 0.81–1.89 0.326 1.15 0.71–1.86 0.565 1.35 0.92–1.98 0.111 0.86 0.63–1.18 0.356
IgG4 1.42 0.33–6.20 0.636 1.71 0.35–8.28 0.503 1.12 0.28–4.53 0.871 0.71 0.24–2.08 0.530
IgM 1.14 0.89–1.47 0.308 1.07 0.85–1.35 0.579 1.06 0.84–1.35 0.609 1.03 0.85–1.26 0.750
EBA-175 IgG 1.43 1.03–1.99 0.029 1.34 0.99–1.81 0.059 1.11 0.81–1.53 0.510 0.90 0.68–1.18 0.430
IgG1 1.48 0.75–2.94 0.257 1.77 0.98–3.21 0.052 0.87 0.35–2.13 0.755 0.49 0.25–0.97 0.026
IgG2 2.50 0.07–84.0 0.609 2.66 0.30–23.5 0.384 0.46 0.03–6.10 0.561 0.37 0.06–2.19 0.264
IgG3 1.58 0.86–2.91 0.139 1.12 0.75–1.67 0.581 1.50 0.73–3.08 0.269 0.44 0.19–0.98 0.037
IgG4 0.69 0.34–1.40 0.300 0.85 0.51–1.39 0.484 0.77 0.31–1.88 0.579 3.07 1.08–8.78 0.020
IgM 1.32 1.02–1.69 0.032 1.24 0.97–1.59 0.086 1.09 0.87–1.39 0.450 1.03 0.85–1.25 0.757
a

Negative binomial regression model using likelihood ratio test crude and adjusted by gender, IPTi treatment, previous malaria episodes, present infection, and neighborhood. The sample size at the two study periods are those indicated in the table in the supplemental material (antibody prevalences) for each antigen and antibody type and for months 5 and 12. IRR, incidence rate ratio.